 SAN DIEGO, Jan. 28, 2021 GLOBE NEWSWIRE -- Oncternal Therapeutics, Inc. Nasdaq: ONCT, a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Rosemary Mazanet, M.D., Ph.D., to its Board of Directors, effective January 27, 2021. Dr. Mazanet has extensive experience in all stages of oncology drug development from investigational new drug submission IND through new drug application NDA approval and commercial launch. 